imatinib mesylate has been researched along with Disease Exacerbation in 403 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 185 (45.91) | 29.6817 |
| 2010's | 202 (50.12) | 24.3611 |
| 2020's | 16 (3.97) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, M; Ishikawa, M; Kanda, Y; Maki, A; Matsumura, I; Nakamae, H; Ohmine, K; Ono, T; Sakaida, E; Shibayama, H; Yamamoto, M | 1 |
| Chang, PY; Chen, JH; Chen, YC; Chen, YG; Chiu, YL; Dai, MS; Ho, CL; Huang, TC; Lai, HF; Lai, SW; Lee, CH; Liu, WN; Wu, YY; Ye, RH | 1 |
| Beg, MMA; Guru, SA; Koner, BC; Mir, R; Saxena, A; Sumi, MP | 1 |
| Cenda, A; Chukwu, O; Jakóbczyk, M; Kamińska, M; Sacha, T; Szczepanek, E; Wącław, J; Wysogląd, H; Zawada, M | 1 |
| Buljan, M; Crnarić, I; Delaš Aždajić, M; Šitum, M; Vučić, M | 1 |
| Bauer, S; Bialick, S; George, S; Gómez-Peregrina, D; Grassian, A; Heinrich, MC; Jones, RL; Kang, YK; Mir, O; Newberry, K; Pantaleo, MA; Rutkowski, P; Schöffski, P; Serrano, C; Shi, H; Tap, WD; Trent, JC; von Mehren, M | 1 |
| Kebbati, Z; Khettab, M; Zidane, H | 1 |
| Giordano, FA; Grimm, M; Groden, C; Hochhaus, A; Hofheinz, R; Sautter, L; Schmieder, K; Tuettenberg, J; Vajkoczy, P; Wenz, F | 1 |
| Blay, JY; Bompas, E; Brahmi, M; Cassier, PA; Desai, J; Eberst, L; Gelderblom, H; Hannink, G; Italiano, A; Maki, RG; Mastboom, MJL; Mir, O; Seddon, BM; Stacchiotti, S; van de Sande, MAJ; van der Graaf, WTA; Verspoor, FGM; Wagner, A | 1 |
| Kaur, G; Piplani, H; Puri, S; Sanyal, SN; Vaish, V | 1 |
| Christov, C; Dicato, M; Diederich, M; Gaigneaux, A; Gérard, D; Grandjenette, C; Mazumder, A; Schnekenburger, M | 1 |
| Astolfi, A; Indio, V; Nannini, M; Pantaleo, MA; Urbini, M | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Chang, W; Chen, S; Chen, Z; Cheng, H; Gale, RP; Guo, J; Jiang, Q; Li, Q; Li, W; Meng, L; Qin, J; Sheng, L; Wan, C; Wang, D; Yang, Z; You, Y; Yuan, G; Zhang, Y; Zhu, X | 1 |
| He, YL; Zhang, XH | 1 |
| Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kimura, Y; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M | 1 |
| Billingsley, KG; Corless, CL; Heinrich, MC; Mayo, SC; Sheppard, BC; Sutton, TL; Walker, BS | 1 |
| Bansod, S; Godugu, C; Saifi, MA | 1 |
| Chen, Q; Chua, SH; Kok, WL; Lee, SSJ; Ng, SK | 1 |
| Li, T; Lin, H; Liu, M; Wu, B; Zhong, H | 1 |
| Cai, HF; Li, N; Liu, MB; Luo, XF; Weng, LZ; Yang, J; Zhan, FM; Zheng, B | 1 |
| Horiuchi, T; Kato, S; Kawamura, T; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Nagao, S; Okada, Y; Saga, R; Sato, K; Tachi, N; Takano, K; Teramoto, M; Watanabe, J; Yamamura, T | 1 |
| Bovée, JVMG; Gelderblom, H; Guchelaar, HJ; Kloth, JSL; Mathijssen, RHJ; Reyners, AKL; Sleijfer, S; Steeghs, N; Swen, JJ; van der Straaten, T; Verboom, MC | 1 |
| Bardy-Bouxin, N; Brümmendorf, TH; Chuah, C; Cortes, JE; Deininger, MW; Dyagil, I; Gambacorti-Passerini, C; Garcia-Gutierrez, V; Glushko, N; Hochhaus, A; Jeynes-Ellis, A; Kim, DW; le Coutre, P; Leip, E; Mauro, MJ; Milojkovic, D; Reilly, L | 1 |
| Iwamatsu, K; Kimura, A; Kogure, N; Kuwano, H; Nakazawa, N; Ogata, K; Suzuki, M; Ubukata, Y; Yanai, M; Yanoma, T | 1 |
| Bennaceur-Griscelli, A; Bonnet, ML; Cayssials, E; Chomel, JC; Desterke, C; Pagliaro, S; Rahban, H; Sorel, N; Turhan, AG; Voldoire, M | 1 |
| Aleinikova, O; Balduzzi, A; Berthold, F; Borkhardt, A; Claviez, A; de Bont, ESJM; Eggert, A; Glauche, I; Göhring, G; Groll, AH; Groß-Wieltsch, U; Harbott, J; Henze, G; Klein, C; Kreipe, HH; Kremens, B; Krumbholz, M; Kulozik, AE; Lausen, B; Metzler, M; Nowasz, C; Schlegelberger, B; Schrappe, M; Schulze, P; Sedlacek, P; Strauss, G; Sufliarska, S; Suttorp, M; Sykora, KW; Tauer, JT; Thiede, C; von Neuhoff, N | 1 |
| Arribas, J; Carles, J; Díaz-Beveridge, R; Durán, J; Estival, A; García-Del-Muro, X; Hernández-Losa, J; Hindi, N; Jiménez, L; Landolfi, S; Lavernia, J; Manzano, A; Martínez-Marín, V; Pajares, I; Pericay, C; Rubió-Casadevall, J; Safont, MJ; Sebio, A; Serrano, C; Valverde, C; Vicente-Baz, D; Vivancos, A | 1 |
| Abecasis, J; Afonso, C; Gouveia, R; Strong, C; Trabulo, M | 1 |
| Brich, S; Casale, A; Casali, PG; Cavalleri, A; Collini, P; Dinoi, G; Frezza, AM; Gronchi, A; Lo Vullo, S; Mariani, L; Messina, A; Morelli, D; Morosi, C; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Venturelli, E | 1 |
| Angelini, S; Astolfi, A; Biasco, G; Brandi, G; Gatto, L; Genovese, C; Hrelia, P; Ianni, M; Indio, V; Nannini, M; Pantaleo, MA; Ravegnini, G; Saponara, M; Simeon, V; Trino, S; Urbini, M | 1 |
| Bombelli, S; Boultwood, J; Branford, S; Citterio, S; Crespiatico, I; D'Aliberti, D; Fontana, D; Gambacorti-Passerini, C; Khandelwal, P; Kim, DW; Magistroni, V; Massimino, L; Mauri, M; Mezzatesta, C; Morotti, A; Nava, M; Parker, W; Perego, R; Piazza, R; Pirola, A; Readelli, S; Rigolio, R; Saglio, G; Schreiber, A; Sharma, N; Viltadi, M; Wang, P; Yeung, D | 1 |
| Abruzzese, E; Annunziata, M; Baccarani, M; Berchialla, P; Bergamaschi, M; Bocchia, M; Breccia, M; Caocci, G; Capodanno, I; Castagnetti, F; Cattaneo, D; Cavazzini, F; Cedrone, M; Cerrano, M; Crugnola, M; Dogliotti, I; Dragani, M; Elena, C; Fava, C; Ferrero, D; Galimberti, S; Gambacorti-Passerini, C; Giai, V; Gozzini, A; Gugliotta, G; Iuliano, F; Iurlo, A; Latagliata, R; Levato, L; Luciano, L; Lunghi, F; Martino, B; Musto, P; Pane, F; Pregno, P; Rapezzi, D; Rege-Cambrin, G; Rosti, G; Russo, S; Saglio, G; Santoro, M; Sgherza, N; Sorà, F; Specchia, G; Stagno, F | 1 |
| Chandran, RK; Geetha, N; Krishna, KMNJ; Kumar, RS; Sakthivel, KM; Sreedharan, H | 1 |
| Alunni Fegatelli, D; Breccia, M; Chiatamone Ranieri, S; Colafigli, G; Diverio, D; Efficace, F; Foà, R; Latagliata, R; Molica, M; Rizzo, L; Scalzulli, E | 1 |
| Ayemou, R; Djoko, S; Emeuraude, N; Kamara, I; Koffi, G; Kouakou, B; Meité, N; Nanho, CD; Sanogo, I; Silué, DA; Sowhe, T; Tolo, A | 1 |
| Ekert, K; Hinterleitner, C; Horger, M | 1 |
| Almeida, AM; Alves, R; Freitas-Tavares, P; Gonçalves, AC; Jorge, J; Luís, D; Marques, G; Oliveiros, B; Ribeiro, AB; Sarmento-Ribeiro, AB | 1 |
| Gielen, GH; Herrlinger, U; Keil, VC; Schäfer, N; Weller, JM | 1 |
| Cho, H; Kang, YK; Kim, BS; Kim, CW; Kim, JH; Kim, KH; Lee, SM; Lee, Y; Park, Y; Park, YS; Ryu, MH; Yoo, MW | 1 |
| Ding, L; He, Q; Wang, T; Yang, B; Yao, F; Yao, Z; Zhang, B; Zhang, J; Zhong, T | 1 |
| De Souza, C; Etienne, G; Fan, X; Hochhaus, A; Hoenekopp, A; Hughes, TP; Kalaycio, ME; Kantarjian, HM; Kim, DW; Kurokawa, M; Larson, RA; Rosti, G; Saglio, G; Shou, Y | 1 |
| Patel, S | 2 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Chen, L; Griffin, JD; Guerin, A; Ionescu-Ittu, R; Luo, J; Macalalad, AR; Wu, EQ | 1 |
| Mucke, H | 1 |
| Alimoghaddam, K; Chahardouli, B; Ghavamzade, A; Kazemi, A; Mousavi, SA; Nadali, F; Ostadali, M; Rostami, S; Zaker, F | 1 |
| Chen, MF; Chiang, KC; Fu, CJ; Jan, YY; Yeh, CN; Yen, TC | 1 |
| DeMatteo, RP; Demetri, G | 1 |
| Hornick, JL; Jagannathan, JP; Ramaiya, NH; Tirumani, SH | 1 |
| Arthur, C; Branford, S; Dang, P; Filshie, RJ; Goyne, JM; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C; White, DL; Yeung, DT | 1 |
| Pardanani, A | 1 |
| Bauer, S; Bonvalot, S; Bylina, E; Casali, PG; Cats, A; de Wilt, JH; Fiore, M; Fumagalli, E; Gronchi, A; Hohenberger, P; Hoiczyk, M; Kerst, JM; Le Cesne, A; Nguyen, BP; Nyckowski, P; Rutkowski, P; Schöffski, P; Sleijfer, S; Stoeckle, E; Tielen, R; Treckmann, J; van Coevorden, F; van der Graaf, W; Verhoef, C | 1 |
| Fan, WC; Hsieh, JS; Huang, CJ; Yin, TC | 1 |
| Kamiryo, Y; Kinjo, M; Okumura, K; Otsubo, S; Shimokama, T | 1 |
| Lee, SR; Yhim, HY | 1 |
| Chen, L; Guo, A; Liu, J; Marynchenko, M; Sharma, H; Shi, L; Vander Velde, N; Wu, EQ; Yang, H | 1 |
| Choi, YJ; Jo, J; Kang, YK; Lee, JJ; Park, I; Park, JH; Ryoo, BY; Ryu, JS; Ryu, MH; Tan, E; Yoo, C | 1 |
| Leser, U; Leutz, A; Rosenbauer, F; Scheller, M; Schönheit, J; Zimmermann, K | 1 |
| Kawachi, H; Khadzhynov, D; Loof, T; Mika, A; Neumayer, HH; Peters, H; Wang-Rosenke, Y | 1 |
| Blay, JY; Joensuu, H; Le Cesne, A; Reichardt, P | 1 |
| Demetri, GD; Jagannathan, J; Kang, YK; Kim, HJ; Lee, JJ; Nam, BH; Ramaiya, N; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Baerlocher, GM; Dengler, J; Ehninger, G; Einsele, H; Fabarius, A; Falge, C; Haferlach, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Pletsch, N; Proetel, U; Saußele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Béogo, R; Hien, FM; Ouédraogo, GA; Sawadogo, S; Toguyeni, A | 1 |
| Aboulafia, D; Dezube, BJ; Honda, K; Koon, HB; Krown, SE; Lee, JY; Noy, A; Rapisuwon, S; Reid, EG; Rudek, MA; Wang, Z | 1 |
| Bertola, G; Buonadonna, A; Canzonieri, V; Gasparotto, D; Libra, M; Maestro, R; Marzotto, A; Miolo, G; Torrisi, E | 1 |
| Blanchard, F; Brion, R; Charrier, C; Gobin, B; Heymann, D; Moriceau, G; Ory, B; Redini, F | 1 |
| Abdulsahib, MA; Alwan, AF; Matti, BF; Muhammed, AH; Naji, AS | 1 |
| Li, Y; Luo, J; Pan, Y; Shang, Y; Yang, J; Yang, L | 1 |
| Kanehara, I; Kitayama, K; Nishino, H; Nomura, S; Teraoka, H; Toyokawa, T | 1 |
| Liang, X; Shi, Y | 1 |
| Cao, H; Du, CY; He, YL; Jie, ZG; Liang, XB; Shi, YQ; Song, C; Wang, YP; Yan, ZS; Zhou, Y | 1 |
| Gravitz, L | 1 |
| Kang, YK; Kim, BS; Kim, CW; Kim, HJ; Kim, KH; Park, SJ; Park, YS; Ryoo, BY; Ryu, MH; Sohn, BS; Yook, JH; Yu, CS | 1 |
| Chung, KM; Lai, EC; Lau, SH; Lau, WY | 1 |
| Bai, R; Cerny, J; Druker, BJ; Eide, CA; Green, MR; Hutchinson, L; Khoury, HJ; Li, S; Ma, L; Ou, J; Shan, Y; Sheng, Z; Xue, L; Zhu, LJ | 1 |
| Brzuszkiewicz, K; Bylina, E; Limon, J; Osuch, C; Rutkowski, P; Siedlecki, JA | 1 |
| Chang, YR; Han, IW; Jang, JY; Kang, MJ; Kim, SW; Kwon, W; Lee, HJ; Lee, KB; Park, JW; Park, KJ | 1 |
| Takahashi, N | 1 |
| Drabo, YJ; Hien, FM; Ouédraogo, MS; Sawadogo, S | 1 |
| Amini, M; Campagna, D; Dei Tos, AP; Gasparotto, D; Maestro, R; Marzotto, A; Rossi, S; Scavina, P; Tiziano, FD; Toffolatti, L; Vitelli, CE | 1 |
| Boglione, A; Comandone, A | 1 |
| Adamaki, M; Athanasiadou, A; Divane, A; Karytianou, A; Moschovi, M; Tourkantoni, N | 1 |
| Burchert, A; Dengler, J; Dietz, CT; Fabarius, A; Falge, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heinrich, L; Hochhaus, A; Kalmanti, L; Kanz, L; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Oppliger-Leibundgut, E; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Rinaldetti, S; Saussele, S; Scheid, C; Spiekermann, K; Stegelmann, F | 1 |
| Pagani, IS; Pirrone, C; Porta, G | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Nakatsuka, R; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
| Cui, ZG; Li, GL; Shi, X; Wang, YY; Xu, H; Zhao, HG; Zhao, T; Zhou, Y | 1 |
| Barrios, CH; Blackstein, ME; Blay, JY; Casali, PG; Chacon, M; Gu, J; Kang, YK; Nishida, T; Purkayastha, D; Reichardt, P; Woodman, RC | 1 |
| Hirota, S; Ishikawa, T; Kanda, T; Kosugi, SI; Naito, T; Ueki, K; Wakai, T | 1 |
| Badalamenti, G; Bronte, G; Casali, P; De Lisi, D; Dei Tos, AP; Frezza, AM; Fumagalli, E; Nannini, M; Pantaleo, MA; Russo, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vincenzi, B | 1 |
| Baróti, BÁ; Benedek Lázár, E; Dénes, L; Horváth, A; Pap, Z; Pávai, Z; Szántó, A; Tunyogi, AB | 1 |
| Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G | 1 |
| Ambavane, A; Bolinder, B; Felber, E; Makenbaeva, D; Stillman, I; Whalen, J | 1 |
| Abouelfath, A; Adenis, A; Blay, JY; Bompas, E; Bouché, O; Bouchet, S; Bui, B; Chevreau, C; Collard, O; Cupissol, D; Duffaud, F; Italiano, A; Lassalle, R; Le Cesne, A; Molimard, M; Moore, N; Poulette, S; Ray-Coquard, I; Rios, M; Titier, K | 1 |
| Bauer, S; Gruenwald, V; Haller, F; Hohenberger, P; Kasper, B; Reichardt, P | 1 |
| Csef, EJ; Hefner, J; Kunzmann, V | 1 |
| Bozkurt, S; Büyükaşık, Y; Eyüpoğlu, D; Güven, D; Haznedaroğlu, İ | 1 |
| Abraham, I; Dong, Y; Kim, DW; Segar, JM; Shen, Y; Vincelette, ND; Yun, S | 1 |
| Amini, L; Dörken, B; Gresse, M; Kaeda, J; le Coutre, P; Oberender, C; Ringel, F; Schwarz, M | 1 |
| Fang, L; Li, J; Tu, H; Wan, Q; Wu, Q; Yang, Y; Zhang, X | 1 |
| Agatheeswaran, S; Chakraborty, S | 1 |
| Angelkovic, R; Cevreska, L; Genadieva-Stavric, S; Pavkovic, M; Popova-Simjanovska, M; Stojanovic, A | 1 |
| Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Lipton, JH; Matczak, E; Noonan, K; Schafhausen, P | 1 |
| Le Cesne, A; Patrikidou, A | 1 |
| Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH | 1 |
| Bhat, M; Farooq, S; Gupta, N; Guru, S; Javaid, J; Masroor, M; Mir, R; Najar, IA; Ray, PC; Saxena, A; Yadav, P; Zuberi, M | 1 |
| Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T | 1 |
| Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C | 1 |
| Cao, H; Wang, M | 1 |
| Lei, C; Liu, L; Wang, H; Wang, Q | 1 |
| Choi, JR; Kim, Y; Lee, KA; Shin, S; Yu, N | 1 |
| Fu, Y; Guo, L; Hao, H; Yang, G; Zhang, X | 1 |
| Brower, V | 1 |
| Carré, M; Charbonnier, A; Dubruille, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Ianotto, JC; Legros, L; Mahon, FX; Nicolini, F; Noel, MP; Rea, D; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Varet, B; Villemagne, B | 1 |
| Fujiwara, Y; Fukuda, S; Inoue, M; Kitani, K; Ohta, Y; Tsujie, M; Wakasa, T; Yukawa, M | 1 |
| Bauer, S; Dimitrakopoulou-Strauss, A; Gruenwald, V; Haller, F; Hohenberger, P; Kasper, B; Limprecht, R; Pilz, L; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Bleickardt, E; Charbonnier, A; Collins, RH; Deininger, M; Dorlhiac-Llacer, PE; Francis, S; Hochhaus, A; Hughes, T; Kantarjian, HM; Khoroshko, N; Khoury, HJ; Kim, DW; Milone, JH; Otero, I; Paquette, RL; Réa, D; Shah, NP; Silver, RT; Strauss, L; Vela-Ojeda, J | 1 |
| Heger, U; Lordick, F; Weitz, J | 1 |
| Clisant, S; Delcambre, C; Durando, X; Fournier, C; Hebbar, M; Isambert, N; Mascarelli, F; Mouriaux, F; Negrier, S; Penel, N | 1 |
| Tuma, RS | 1 |
| Apperley, JF; Bua, M; de Lavallade, H; Goldman, JM; Kaeda, J; Khorashad, JS; Marin, D; Milojkovic, D; Olavarria, E; Reid, AG; Szydlo, R | 1 |
| Distler, JH; Distler, O; Manger, B; Schett, G; Spriewald, BM | 1 |
| Dik, WA; Hooijkaas, H; Thio, HB; van Daele, PL; van Hagen, PM; van Hal, PT; van Laar, JA | 1 |
| Dienes, HP; Engelmann, U; Gerharz, M; Heidenreich, A; Markert, E; Ohlmann, CH; Pfister, D | 1 |
| Chen, SJ; Chen, Z; Fu, JF; Hu, J; Jin, J; Li, JM; Pan, Q; Shi, JY; Wang, LN; Zhao, WL | 1 |
| Albitar, M; Cortes, J; Estrov, Z; Giles, F; Hannah, A; Kantarjian, H; Keating, M; O'Brien, S; Tseng, R; Yeh, CH; Zhang, Z | 1 |
| Bar-Eli, M; Bedikian, AY; Billings, LA; Camacho, LH; Charnsangavej, C; Cormier, JN; Davis, DW; Diwan, AH; Eton, O; Frazier, ML; Gershenwald, JE; Johnson, MM; Kim, KB; Lee, JE; Mansfield, PF; McConkey, DJ; Murgo, AJ; Ng, CS; Papadopoulos, NE; Prieto, VG; Ross, MI | 1 |
| Brandes, AA; Clement, PM; Coudert, B; Dittrich, C; Frenay, M; Fumoleau, P; Gorlia, T; Heinrich, MC; Kros, JM; Lacombe, D; Rampling, R; Raymond, E; Stupp, R; van den Bent, MJ | 1 |
| Antonescu, CR; Corless, CL; Fletcher, CD; Hornick, JL; Liegl, B | 1 |
| Antonescu, CR; Baum, CM; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Griffith, D; Harlow, A; Heinrich, MC; Huang, X; Maki, RG; McKinley, A; Ou, WB; Town, A | 1 |
| Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N | 1 |
| Imataki, O; Ishida, T; Ohnishi, H; Shintani, T; Waki, F | 1 |
| Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, H; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ | 1 |
| Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R | 1 |
| Brosa, M; Díaz, S; García del Muro, X; González, P; Grande, E; Paz-Ares, L | 1 |
| Baccarani, M; Baldazzi, C; Breccia, M; Castagnetti, F; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Pane, F; Rosti, G; Saglio, G; Specchia, G; Stacchini, M; Testoni, N | 1 |
| Goh, HG; Jang, SE; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH | 1 |
| Branford, S; Druker, BJ; Foroni, L; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Hughes, TP; Larson, RA; Mone, M; Müller, MC; O'Brien, SG; Radich, JP; Rudoltz, M | 1 |
| Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J | 1 |
| Cai, Z; Cao, W; Huang, H; Lai, X; Lin, M; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Xie, W; Ye, X; Zhao, Y | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, H; Kornblau, S; O'Brien, S; Quintás-Cardama, A; Shan, J; Thomas, D | 1 |
| Armbrust, T; Cameron, S; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Sobotta, M | 1 |
| Ceglerek, B; Grygalewicz, B; Konopka, L; Krawczyk, P; Pastwińska, A; Pieńkowska-Grela, B; Rygier, J; Seferyńska, I; Sikorska, A; Woroniecka, R | 1 |
| Godley, LA | 1 |
| Blay, JY; Reichardt, P | 1 |
| Mauro, MJ | 1 |
| Jamedhor, M; Reddy, KS; Schwartz, GE | 1 |
| Blay, JY; Bui, B; Casali, PG; Findlay, M; Hogendoorn, PC; Issels, R; Judson, I; Le Cesne, A; Leyvraz, S; Reichardt, P; Schoffski, P; Sciot, R; Van Glabbeke, M; Verweij, J | 1 |
| Casali, PG; Fiore, M; Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Reichardt, P; Ronellenfitsch, U; Tamborini, E | 1 |
| Fujimoto, J; Hatakeyama, K; Hirota, S; Ishikawa, T; Isozaki, K; Ito, T; Kanda, T; Liu, NN; Matsuda, I; Nakai, N; Shiba, K | 1 |
| Cortes, J; Kantarjian, H; Quintás-Cardama, A | 1 |
| Du, Q; Liu, X; Wang, L; Xu, L; Zhang, S; Zheng, W; Zhu, H | 1 |
| Hackanson, B; Lübbert, M; Rückert, A | 1 |
| Melo, JV; Yong, AS | 1 |
| Reichardt, P | 1 |
| Bailey, SM; Bertulli, R; Blay, JY; Borghaei, H; Casali, PG; Cassier, P; Cheung, W; Davey, M; Debiec-Rychter, M; Demetri, GD; Fumagalli, E; Morgan, JA; Pink, D; Ray-Coquard, I; Reichardt, A; Reichardt, P; Veronese, ML; von Mehren, M | 1 |
| Schatz, DG; Strout, MP | 1 |
| Dundamadappa, SK; Karam, AR; Shankar, S; Stay, RM; van Sonnenberg, E | 1 |
| Jung, CW; Kamel-Reid, S; Kim, DH; Kim, S; Lipton, JH; Liu, X; Xu, W | 1 |
| Hohenberger, P | 2 |
| Call, J; Josephy, PD; Scherzer, NJ; Walentas, C | 1 |
| Bacchi, CE; Lopes, LF | 1 |
| Daniels, CE; Gabor, E; Lasky, JA; Limper, AH; Mieras, K; Schroeder, DR | 1 |
| Gałazka, K; Majewski, M; Rodzaj, M; Zduńczyk, A | 1 |
| Bommer, C; Daniel, P; Dörken, B; Kim, TD; Koca, G; le Coutre, P; Nogai, H; Schwarz, M; Türkmen, S | 1 |
| Ahn, KS; Kim, BK; Kim, KI; Oh, JM; Park, J; Shin, WG; Won, NH; Yoon, SS | 1 |
| Ballestrero, A; Carella, AM; Catania, G; Cirmena, G; Garuti, A; Gobbi, M; Miglino, M; Palermo, C; Patrone, F; Pica, G; Pierri, I; Rocco, I | 1 |
| Du, CY; Fu, H; Huang, K; Shi, YQ; Wang, CM; Ye, YW; Zhou, XY; Zhou, Y | 1 |
| Bee, PC; Gan, GG; Latiff, NA; Menaka, N; Nadarajan, VS | 1 |
| Waller, CF | 1 |
| Redner, RL | 1 |
| Brigid Bradley-Garelik, M; Bullorsky, E; Charbonnier, A; Dombret, H; Ehninger, G; Larson, RA; Lilly, MB; Martinelli, G; Müller, MC; Ottmann, OG; Reiffers, JJ; Shah, NP; Zhu, C | 1 |
| Fullmer, A; Jabbour, E | 1 |
| Deng, D; Lai, Y; Li, Q; Liang, Y; Liu, R; Luo, J; Ma, J; Peng, Z; Schwarzenberger, P; Shi, L; Yang, J; Zhou, J; Zhou, Y | 1 |
| Baker, LH; Verweij, J | 1 |
| Blay, JY; Gronchi, A; Trent, JC | 1 |
| Jamal, Y; Usmani, SZ; Yunus, SA | 1 |
| Giaccone, G; Hogendoorn, PC; Rajan, A; Ruijter, R; Smit, E; van Groeningen, C | 1 |
| Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P | 1 |
| Ahmad, R; Singh, R; Singh, RK; Singh, S; Tripathi, AK; Tripathi, P | 1 |
| Ibrahim, TM; Salem, HA; Shaker, ME; Shiha, GE | 1 |
| Skorski, T | 1 |
| Hou, M; Jiang, M; Yang, Y; Zhou, L; Zhu, J | 1 |
| Ahlman, H; Andersson, A; Nilsson, B; Nilsson, E; Nilsson, O; Sjölund, K | 1 |
| Clark, RE; Dong, M; Etienne, G; Gallagher, N; Haque, A; Hochhaus, A; Hoenekopp, A; Hughes, TP; Issaragrisil, S; Kantarjian, HM; Kim, DW; Larson, RA; le Coutre, P; Lobo, C; Pasquini, R; Saglio, G | 1 |
| Ayala, M; Baccarani, M; Bleickardt, E; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Huguet, F; Kantarjian, H; Mayer, J; Moiraghi, B; Nakamae, H; Pasquini, R; Shah, NP; Shah, S; Shapiro, D; Shen, Z; Szatrowski, T; Zhu, C | 1 |
| Bachmann, K; Brandl, S; Izbicki, JR; Kaifi, JT; Kunkel, M; Rawnaq, T; Sauter, G; Simon, R; Zander, H | 1 |
| Bernheim, A | 1 |
| Blay, JY; Brain, EG; Bui, BN; Chabaud, S; Chevreau, C; Cupissol, D; Duffaud, F; Guillemet, C; Jimenez, M; Le Cesne, A; Mignot, L; Penel, N; Perol, D; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Ramnath, N; Ruckdeschel, JC; Schneider, BJ; Worden, FP; Wozniak, AJ; Zhang, X | 1 |
| Joseph, A; Kingham, BF; Martin, SE; Sausen, M | 1 |
| Karamitopoulou, E; Karatzas, T; Machairas, A; Machairas, N; Misiakos, EP; Tsapralis, D | 1 |
| Kelley, RK; Venook, AP | 1 |
| Abdelhay, E; Amarante-Mendes, GP; Binato, R; Bueno-Da-Silva, AE; Castro, FA; Colassanti, MD; De Carvalho, DD; Jacysyn, JF; Leroy, JM; Pereira, WO; Proto-Siqueira, R; Zago, MA; Zanichelli, MA | 1 |
| Heinrich, MC | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bui, BN; Chabaud, S; Chevreau, C; Cioffi, A; Cupissol, D; Duffaud, F; Emile, JF; Le Cesne, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Coyne, J; Janku, F; Kidney, D | 1 |
| Bauer, S; Grabellus, F; Schmid, KW; Sheu, SY; Speich, N; Worm, K | 1 |
| Hackanson, B; Waller, CF | 1 |
| Allis, CD; Antonescu, CR; Chen, Y; Chi, P; Dewell, S; Fletcher, JA; Guo, X; Maki, RG; Sawyers, CL; Shamu, T; Wongvipat, J; Zhang, L; Zheng, D | 1 |
| Porkka, K; Richter, J; Simonsson, B | 1 |
| Chen, MF; Chen, TW; Chiang, KC; Hwang, TL; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wang, SY; Yeh, CN | 1 |
| Bruce, I; Ghosal, N; Hastings, D; Homer, J; Julyan, P; Mais, K; Ryder, WD; Shenjere, P; Slevin, NJ; Ward, T | 1 |
| Beck, M; Chang, HM; Cho, Y; Choi, DR; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoon, DH | 1 |
| Alacacioglu, A; Camci, C; Dikilitas, M; Er, O; Kalender, ME; Sagol, O; Sari, I; Sevinc, A; Soyuer, I; Yilmaz, U | 1 |
| Conley, A; George, S; Lazar, AJ; Nolden, L; Reynoso, D; Trent, JC; Wang, WL | 1 |
| Tefferi, A | 1 |
| Cerny-Reiterer, S; Dworzak, M; Eckelhart, E; Egger, G; Fajmann, S; Gleixner, KV; Herrmann, H; Hoermann, G; Hölbl, A; Kollmann, K; Mayerhofer, M; Moriggl, R; Sexl, V; Sillaber, C; Valent, P; Warsch, W | 1 |
| Anand, MS; Juneja, SS; Varma, N; Varma, S | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Blesius, A; Bui, B; Cassier, PA; Cupissol, D; Fayette, J; Le Cesne, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Diebold, J; Hirschmann, A; Rössle, M | 1 |
| Argentou, N; Braimi, M; Germenis, AE; Gramoustianou, ES; Karanikas, V; Mandala, E; Matsouka, P; Ritis, K; Speletas, M | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y | 1 |
| Alimena, G; Amabile, M; Baccarani, M; Bocchia, M; Breccia, M; Capucci, A; Castagnetti, F; Ferrero, D; Gherlinzoni, F; Grifoni, F; Gugliotta, G; Intermesoli, T; Martinelli, G; Martino, B; Marzocchi, G; Montefusco, E; Palandri, F; Pane, F; Pierri, I; Pregno, P; Rosti, G; Rupoli, S; Saglio, G; Testoni, N; Tiribelli, M | 1 |
| Cogliatti, SB; Craig, VJ; Müller, A; Rehrauer, H; Wündisch, T | 1 |
| Acosta, JC; Albajar, M; Bermúdez, A; Delgado, MD; Donato, N; Gómez-Casares, MT; León, J; Llorca, J; Mauleon, I; Vaqué, JP | 1 |
| Persano Adorno, D; Pizzolato, N; Spagnolo, B; Valenti, D | 1 |
| Chauncey, TR; Flowers, ME; Georges, GE; Lange, T; Langston, AA; Laport, GG; Maloney, DG; Maris, MB; Ram, R; Sandmaier, BM; Storb, R; Storer, B; Woolfrey, A | 1 |
| Bauer, S; Montemurro, M | 1 |
| Amagasaki, T; Fukuda, T; Kanda, Y; Kurokawa, M; Maeda, Y; Matsuda, A; Nagai, T; Nakamae, H; Nakaseko, C; Ohnishi, K; Shibayama, H; Yanada, M | 1 |
| Baccarani, M; Guilhot, F; Guilhot, J; Hasford, J; Hehlmann, R; Hoffmann, V; Lindoerfer, D; Ossenkoppele, G; Pfirrmann, M; Porkka, K; Rosti, G; Saussele, S; Simonsson, B | 1 |
| Nishida, T; Omori, T; Ueshima, S | 1 |
| Cortes, JE; Kantarjian, HM; Quintás-Cardama, A | 1 |
| Bengió, RM; Bianchini, M; Bullorsky, E; Lanari, E; Larripa, I; Milone, J; Moiraghi, B; Murro, H; Riva, ME; Tezanos Pinto, Md; Ventriglia, V | 1 |
| Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Quayyum, Z; Sharma, P; Vale, L | 1 |
| Leof, EB; Torres, VE | 1 |
| Chung, W; Cortes, JE; Estecio, MR; Gharibyan, V; He, R; Issa, JP; Jelinek, J; Kantarjian, HM; Kondo, K; Liang, S; Lu, Y; Zhang, N | 1 |
| Ben-Bassat, I; Gafter-Gvili, A; Gurion, R; Leader, A; Lishner, M; Raanani, P; Ram, R; Shacham-Abulafia, A; Shpilberg, O; Vidal, L | 1 |
| Ishida, T; Izawa, K; Kobayashi, S; Lin, SF; Tojo, A; Tsai, HJ; Umezawa, K; Watanabe, T | 1 |
| Crespo, O; Daneman, R; Ho, PP; Kang, SC; Lindstrom, TM; Robinson, WH; Sobel, RA; Steinman, L | 1 |
| Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY | 1 |
| Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Sharma, P; Vale, L | 1 |
| Arrigoni, G; Bearzi, I; Capella, C; Casali, PG; Dei Tos, AP; Gnocchi, C; Gronchi, A; Laurino, L; Mariani, L; Mazzoleni, G; Messerini, L; Miceli, R; Rossi, S; Sidoni, A; Sonzogni, A; Toffolatti, L; Vinaccia, V | 1 |
| Chinen, I; Enomoto, T; Hoffman, RM; Kimura, T; Mekada, E; Mizushima, H; Moribe, H; Murata, T; Ueda, Y; Yagi, S; Yoshino, K | 1 |
| Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R | 1 |
| Janssen, JJ; Ossenkoppele, GJ; Schuurhuis, GJ; Thielen, N | 1 |
| Abou-Mourad, YR; Barnett, MJ; Broady, RC; Forrest, DL; Hogge, DE; Nantel, SH; Narayanan, S; Nevill, TJ; Power, MM; Shepherd, JD; Song, KW; Sutherland, HJ; Tantiworawit, A; Toze, CL | 1 |
| Blanke, CD; Demetri, GD; Eisenberg, BL; Heinrich, MC; Hoffman, JP; Kane, JM; Okuno, S; von Mehren, M; Wang, D; Watson, JC; Zhang, Q | 1 |
| da Silveira, CA; Ferrari, I | 1 |
| Juan, WC; Ong, ST | 1 |
| Gao, J; Gong, JF; Li, J; Shen, L; Sun, NP | 1 |
| Fujisawa, S; Imai, K; Kiyoi, H; Maeda, Y; Miyamura, K; Miyazaki, Y; Mori, N; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohtake, S; Takeuchi, J; Tauchi, T; Usui, N; Yagasaki, F; Yamazaki, H | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Bang, JH; Branford, S; Choi, SY; Hughes, TP; Kim, DW; Park, JE; Prime, JA; Ross, DM; Yeung, DT | 1 |
| Gürlich, R; Koldová, L; Kostka, R | 1 |
| Baerlocher, GM; Branford, S; Dengler, J; Einsele, H; Erben, P; Fabarius, A; Falge, C; Göhring, G; Haferlach, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Hughes, TP; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saußele, S; Schnittger, S; Schubert, J; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Atallah, E; Haddad, RY; Torgerson, SR | 1 |
| Borsky, M; Dvorakova, D; Jeziskova, I; Jurcek, T; Mayer, J; Racil, Z; Razga, F; Zackova, D | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Bryant, J; Clegg, A; Colquitt, JL; Cooper, K; Frampton, GK; Loveman, E | 1 |
| Biasco, G; Nannini, M; Pantaleo, MA; Saponara, M | 1 |
| Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C | 1 |
| Appelbaum, FR; Deininger, M; Druker, BJ; Emanuel, P; Kamel-Reid, S; Kopecky, KJ; Larson, RA; Lipton, J; Malnassy, G; Paietta, E; Radich, JP; Stock, W; Tallman, M; Turner, AR; Wadleigh, M | 1 |
| Wardelmann, E | 1 |
| Beumer, JH; Cotarla, I; Deeken, J; Egorin, MJ; Elston, B; Firozvi, K; Hartley, ML; He, AR; Hwang, J; Koh, EY; Liu, M; Malik, S; Marshall, JL; Pishvaian, MJ; Slack, R; Strychor, S | 1 |
| Abdallah, BY; Bremer, SW; Heng, HH; Horne, SD; Liu, G; Stevens, JB; Ye, CJ | 1 |
| Akizawa, T; Iyoda, M; Kuno, Y; Matsumoto, K; Shibata, T; Shindo-Hirai, Y; Wada, Y | 1 |
| Angelini, S; Biasco, G; Cantelli-Forti, G; Casali, PG; Cavrini, G; Di Battista, M; Fumagalli, E; Hrelia, P; Nannini, M; Palassini, E; Pantaleo, MA; Ravegnini, G; Saponara, M; Zenesini, C | 1 |
| Bekers, DJ; Eechoute, K; Krestin, GP; Mathijssen, RH; Ruggiero, A; Schiavon, G; Schöffski, P; Sleijfer, S; van der Holt, B; Vandecaveye, V; Verweij, J | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bui, BN; Chabaud, S; Chevreau, C; Cupissol, D; Domont, J; Duffaud, F; Le Cesne, A; Patrikidou, A; Pérol, D; Ray-Coquard, I; Rios, M | 1 |
| Shannon, KM | 1 |
| Apperley, JF; Armstrong, L; Bua, M; Goldman, JM; Marin, D; Marktel, S; Olavarria, E | 1 |
| Berkowitz, LR; Dunphy, CH; Hall, MD; Hogan, C; Koehler, J; Mitchell, BS; Orlowski, RZ; Shea, TC; van Deventer, HW | 1 |
| Bhalla, K; Fuino, L; Nimmanapalli, R; Richon, V; Stobaugh, C | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Clark, RE; Lin, K; Salim, R; Wang, L | 1 |
| Arlinghaus, R; Cortes, J; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Arthur, C; Branford, S; Grigg, A; Herrmann, R; Hughes, T; Joske, D; Lynch, K; Parkinson, I; Rudzki, Z; Seymour, JF; Szer, J; Taylor, K; Walsh, S | 1 |
| Baccarani, M; Bolton, AE; Capdeville, R; Cervantes, F; Cornelissen, JJ; Druker, BJ; Fischer, T; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Lechner, K; Nielsen, JL; O'Brien, SG; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Taylor, K; Verhoef, G | 1 |
| Apperley, JF; Bua, M; Dazzi, F; De Melo, VA; Foot, N; Goldman, JM; Karadimitris, A; Kotzampaltiris, P; Marin, D; Marktel, S; Olavarria, E; Rahemtulla, A; Szydlo, R | 1 |
| Drechsler, M; Haas, R; Herold, C; Hildebrandt, B; Kronenwett, R; Redmann, A; Royer-Pokora, B; Wieland, C | 1 |
| Berlanga, J; Büchler, T; Encuentra, M; Ferra, C; Gallardo, D; Grañena, A; Hermosilla, M; Sarra, J | 1 |
| Deininger, MW; O'Brien, SG | 1 |
| Hochhaus, A | 1 |
| Preudhomme, C; Roche-Lestienne, C | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S | 1 |
| Chevalier, TL; Johnson, BE; Soria, JC | 1 |
| Aichele, O; Brümmendorf, T; Denzlinger, C; Kanz, L; Kröber, SM; Schittenhelm, M | 1 |
| Apperley, JF; Bua, M; Foot, N; Goldman, JM; Kanfer, E; Klein, JP; Marin, D; Marktel, S; Olavarria, E; Shepherd, P; Szydlo, R | 1 |
| Blay, JY; Brown, M; di Paola, ED; Hogendoorn, PC; Judson, I; Le Cesne, A; Nielsen, OS; Radford, J; Rodenhuis, S; van der Graaf, W; van Oosterom, A; Verweij, J | 1 |
| Dimitrijevic, S; Dunlop, D; Fischer, B; Fischer, T; Fletcher, C; Hornick, J; Johnson, BE; Kowalski, MO; Le Chevalier, T; Rischin, D; Salgia, R; Sayles, D; Silberman, S | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S; Min, CK | 1 |
| Berger, U; Hehlmann, R | 1 |
| Kim, R; Toge, T | 1 |
| Capdeville, R; Dressman, MA; Gathmann, I; Hensley, M; Malinowski, R; McLean, LA; Polymeropoulos, MH | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, HM; Luthra, R; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; Verstovsek, S | 1 |
| Brink, I; Dirnhofer, S; Hartmann, M; Jakob, A; Marx, A; Mikesch, K; Ströbel, P | 1 |
| Brûmmendorf, T; Drummond, M; Holyoake, T; Lennard, A | 1 |
| Brandes, AA; Nicolardi, L; Tosoni, A | 1 |
| Cortes, J | 1 |
| Nguyen, PL; Wahner, AE; Xu, Y | 1 |
| Benjamin, RS; Burgess, MA; Chen, LL; Choi, H; Feig, BW; Frazier, ML; Fuller, GN; Hayes, KJ; Hittelman, W; Hunt, KK; Macapinlac, HA; Oyedeji, CO; Patel, S; Pollock, RE; Prieto, VG; Ramdas, L; Raymond, AK; Trent, JC; Velasco, MA; Wu, EF; Zhang, W | 1 |
| Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C | 1 |
| Deininger, M; Loriaux, M | 1 |
| Blay, JY; Bompas, E; Velay, B | 1 |
| Berthaud, P; Brun-Strang, C; Guilhot, F; Michallet, M; Rousselot, P; Sambuc, R; Tardieu, S | 1 |
| Gordois, A; Scuffham, P; Ward, S; Warren, E | 1 |
| Cilloni, D; Giugliano, E; Mattioli, G; Messa, E; Morotti, A; Rege-Cambrin, G; Saglio, G; Volpe, G | 1 |
| Bikfalvi, A; de Lafarge, B; Eichmann, A; Gilges, D; Hagedorn, M; Javerzat, S; Meyre, A | 1 |
| Bonvalot, S | 1 |
| Azzoli, CG; Crapanzano, JP; Dunne, M; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Rizvi, N; Tyson, L | 1 |
| Abruzzese, E; Alberti, D; Amabile, M; Baccarani, M; Bassi, S; Castagnetti, F; Cilloni, D; de Vivo, A; Fava, M; Giannini, B; Izzo, B; Luatti, S; Martinelli, G; Pane, F; Poerio, A; Rosti, G; Saglio, G; Soverini, S; Testoni, N; Trabacchi, E | 1 |
| Chen, J; Ebert, MP; Gschaidmeier, H; Hosius, C; Kahl, S; Malfertheiner, P; Nitsche, B; Röcken, C | 1 |
| Hitre, E; Láng, I | 1 |
| Chang, Y; Chen, SS; Fu, JY; Jiang, B; Jiang, H; Jiang, Q; Li, JL; Liu, YR; Lu, DP; Qin, YZ; Qiu, JY; Ruan, GR; Wang, H | 1 |
| Baas, P; Dalesio, O; Mathy, A; van Zandwijk, N | 1 |
| Apperley, JF; Bacigalupo, A; Brune, M; Crawley, C; Gratwohl, A; Juliusson, G; Komarnicki, M; Lalancette, M; Lange, A; Mayer, J; Nagler, A; Niederwieser, D; Passweg, J; Rambaldi, A; Ringden, O; Sierra, J; Szydlo, R; Vitek, A; Zander, A | 1 |
| Adjei, AA; Aubry, MC; Dy, GK; Jett, JR; Langdon, RM; Mandrekar, SJ; Miller, AA; Morton, RF; Schild, SE | 1 |
| Blay, JY; Brown, M; Casali, PG; Judson, IR; Le Cesne, A; Reichardt, P; Schlemmer, M; Van Glabbeke, M; Verweij, J; Zalcberg, JR | 1 |
| Bertulli, R; Brown, M; Casali, PG; Goldstein, D; Hogendoorn, PC; Hohenberger, P; Judson, IR; Le Cesne, A; Ray-Coquard, I; Schlemmer, M; Sciot, R; Van Glabbeke, M; van Oosterom, AT; Verweij, J | 1 |
| Khoroshko, ND; Kokhno, AV; Nemchenko, IS; Semenova, EA; Sokolova, MA; Turkina, AG; Zakharova, AV | 1 |
| Decosterd, LA; Ledermann, M; Neef, M; Reichen, J; Rochat, B; Saegesser, H; Schneider, V; Widmer, N | 1 |
| Brownlow, N; Dibb, NJ; Domin, J; Taylor, JR | 1 |
| Agirre, X; Barrios, M; Castillejo, JA; Cervantes, F; Colomer, D; Garate, L; Heiniger, A; Jimenez-Velasco, A; Navarro, G; Prosper, F; Roman-Gomez, J; Sanchez, J; Torres, A | 1 |
| Anthuber, M; Dietmaier, W; Hofstädter, F; Iesalnieks, I; Jantsch, T; Rümmele, P; Schlitt, HJ; Zülke, C | 1 |
| Hong, RL; Hsu, C; Jeng, YM; Lin, CH; Tzen, CY; Yen, RF | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M | 1 |
| Belhorn, T; Blatt, J; Fordham, LA; McDonald, M; McLean, T; Smith, SV; Woods, C | 1 |
| Allred, J; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Kimlinger, T; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE | 1 |
| Denis, N; Dubreuil, P; Kosmider, O; Lacout, C; Moreau-Gachelin, F; Vainchenker, W | 1 |
| Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Chen, SS; Jiang, B; Jiang, H; Jiang, Q; Lu, DP; Lu, Y | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Sohn, HJ | 1 |
| Ault, P; Beran, M; Cortes, J; Faderl, S; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M | 1 |
| Beuthien-Baumann, B; Dittert, DD; Froehner, M; Schuler, U; Wirth, MP | 1 |
| Brames, MJ; Corless, CL; Einhorn, LH; Heinrich, MC; Madani, A | 1 |
| Dai, H; Druker, B; Friend, S; Linsley, PS; Mao, M; Oehler, V; Radich, JP; Sawyers, C; Schelter, J; Shah, N; Stock, W; Willman, CL | 1 |
| Branford, S; Hughes, TP; Moore, S; Ross, DM | 1 |
| Abruzzo, LV; Han, X; Jones, D; Lin, P; Medeiros, LJ | 1 |
| Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M | 1 |
| Dziewirski, W; Grzesiakowska, U; Krawczyk, M; Nasierowska-Guttmejer, A; Nowecki, Z; Nyckowski, P; Ruka, W; Rutkowski, P | 1 |
| Boultwood, J; Campbell, LJ; Eagleton, H; Fidler, C; Gal, S; Kusec, R; Littlewood, TJ; Peniket, A; Wainscoat, JS | 1 |
| Benjamin, RS; Choi, H; Medeiros, LJ; Oyarzo, M; Raymond, AK; Steinert, DM; Thall, PF; Trent, JC; Wang, X; Zhang, W | 1 |
| Druker, BJ; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Krahnke, T; Larson, RA; Massimini, G; O'Brien, S; Roy, L; So, C | 1 |
| Mutti, L; Porta, C; Tassi, G | 1 |
| Cools, J; Debiec-Rychter, M; Folens, C; Marynen, P; Mentens, N; Prenen, H; Schöffski, P; Sciot, R; Van Oosterom, A | 1 |
| Bornmann, WG; Cepero, E; Clarkson, B; de Stanchina, E; Emig, M; Fridman, JS; Hochhaus, A; Kogan, SC; Lowe, SW; McCombie, WR; Ray, S; Veach, DR; Wendel, HG | 1 |
| Bertagnolli, MM; Demetri, GD; Desai, J; Fletcher, CD; George, S; Morgan, JA; Posner, M; Raut, CP; Zahrieh, D | 1 |
| Benjamin, RS; Trent, JC | 1 |
| Cortes, J; Quintás-Cardama, A | 1 |
| Brors, B; Fabarius, A; Frank, O; Gretz, N; Haak, M; Hehlmann, R; Hochhaus, A; Li, L; Merk, S; Müller, MC; Schwindel, U; Seifarth, W; Zheng, C | 1 |
| Linton, KM; Radford, JA; Taylor, MB | 1 |
| Fidler, IJ | 1 |
| Kapelushnik, J; Manor, E; Moser, AM; Narkis, G | 1 |
| Benjamin, RS; Chirieac, LR; Choi, H; Patel, SR; Raymond, AK; Steinert, DM; Trent, JC; Yang, Y; Zhang, J | 1 |
| Blanke, C | 1 |
| Cottin, V | 1 |
| Cortes, J; Giles, F; Kantarjian, HM; O'Brien, S; Talpaz, M | 1 |
| Bidoli, P; Casali, PG; Casieri, P; Miselli, F; Negri, T; Orsenigo, M; Piacenza, C; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Michor, F | 1 |
| Agarwal, P; Amadori, S; Apperley, J; Baccarani, M; Branford, S; Bullorsky, EO; de Souza, CA; Gollerkeri, A; Guilhot, F; Heim, D; Hochhaus, A; Kim, DW; Larson, RA; Lipton, JH; Muller, MC; Roboz, GJ; Talpaz, M | 1 |
| Hoshino, T; Isoda, A; Mitsui, T; Nakahashi, H; Yoshida, Y | 1 |
| Dwyer, JP; Fogo, AB; Koury, MJ; Stone, WJ; Sumner, EL; Wang, Y; Yates, KM; Zent, R | 1 |
| Schulick, RD | 1 |
| Arora, M; Giralt, SA; Goldman, JM; Horowitz, MM; Lee, SJ; Maziarz, RT; McCarthy, PL; Sobocinski, KA | 1 |
| Darwiche, SS; El-Kinge, N; Jamali, FR; Soweid, AM; Tawil, A | 1 |
| Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Faria, SC; Macapinlac, HA; Patel, SR; Podoloff, DA | 1 |
| Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Macapinlac, HA; Patel, SR; Podoloff, DA | 1 |
| Colomer, D; Espinet, B; Feliu, E; Granada, I; Grau, J; Juncà, J; Millá, F; Navarro, JT; Oriol, A; Ribera, JM | 1 |
| Wodarz, D | 1 |
| Seynaeve, C; Sleijfer, S; Verweij, J; Wiemer, E | 1 |
| Beelen, DW; Elmaagacli, AH; Koldehoff, M; Steckel, NK | 1 |
| Bee, PC; Gan, GG; Haris, AR; Teh, A | 1 |
| Bubley, G; Derynck, MK; Lin, AM; Park, M; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V | 1 |
| Chen, X; Chen, Z; He, Y; Huang, S; Li, H; Li, X; Liu, J; Yang, J; Zheng, J | 1 |
| Anderson, B; Barcos, M; Kakati, S; Wetzler, M; Zeidan, A | 1 |
| Boyar, MS; Taub, RN | 1 |
| Bono, P; Bosselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Jalava, T; Joensuu, H; Laurent, D; Putzu, C; Spreafico, C | 1 |
| Demetri, G; Judson, I | 1 |
| Burris, HA; Grapski, R; Greco, FA; Hainsworth, JD; Mallidi, PV; Meng, C; Schreeder, M; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Bock, O; Buesche, G; Frye, B; Gadzicki, D; Ganser, A; Hecker, H; Kreipe, H; Schlegelberger, B; von Neuhoff, N | 1 |
| Becze, E | 1 |
| Oestreicher, P | 1 |
| Dorshkind, K; Witte, ON | 1 |
| Shah, NP | 1 |
| Al-Batran, SE; Dechow, C; Düx, M; Fischer, T; Hartmann, JT; Heidel, F; Izbicki, JR; Jäger, E; Kraus, T; Stoehlmacher, J; Wardelmann, E | 1 |
| Abakumov, EM; Abdulkadyrov, KM; Afanas'ev, BV; Chelysheva, EIu; Chernova, OA; Domracheva, EV; Druzhkova, GA; Goriacheva, SR; Ivanova, VL; Khoroshko, ND; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Kruglov, SS; Krylova, IV; Kuznetsov, SV; Liamkina, AS; Lomaia, EG; Loria, SS; Machiulaĭtene, ER; Martynkevich, IS; Nemchenko, IS; Ogorodnikova, IuS; Pospelova, TI; Shneĭder, TV; Sokolova, MA; Turkina, AG; Udal'eva, VIu; Vakhrusheva, MV; Vinogradova, OIu; Zakharova, AV; Zakharova, ES; Zaritskiĭ, AIu; Zhuravlev, VS | 1 |
| Cortes, J; Druker, B; Fischer, T; Gambacorti, C; Gambacorti-Passerini, C; Goldman, J; Guilhot, F; Hochhaus, A; Kantarjian, HM; Krahnke, T; Mone, M; Niederwieser, DW; O'Brien, SG; Reiffers, JJ; Sawyers, C; Schiffer, CA; Stone, RM; Talpaz, M | 1 |
| Bagg, A; Ou, J; Vergilio, JA | 1 |
| Wassmann, B | 1 |
| Bui, B; Italiano, A | 1 |
| Patel, S; Zalcberg, JR | 1 |
| Blanke, CD; Corless, CL; Demetri, GD; Eisenberg, B; Fletcher, CD; Fletcher, JA; Heinrich, MC; Heinz, D; Joensuu, H; Nikolova, Z; Roberts, PJ; von Mehren, M; Wehre, E | 1 |
| Jatchavala, J; Phaisanphrukkun, C; Phongkitkarun, S; Sirachainan, E | 1 |
| Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A | 1 |
| Capdeville, R; Ford, JM; Gathmann, I; Hatfield, A; Krahnke, T; Van Hoomissen, I | 1 |
| Amato, RJ; Hernandez-McClain, J; Jac, J | 1 |
| Choi, H | 1 |
| Van den Abbeele, AD | 1 |
| Gharibo, M; Guensch, L; Juvidian, P; Patrick-Miller, L; Poplin, E; Zheng, L | 1 |
| White, DL | 1 |
| De Giorgi, U; De Simone, M; Fayyaz, M; Fiorentini, G; Montenora, I; Morini, S; Pupi, A; Turrisi, G | 1 |
| Katayama, Y; Matsui, T; Minagawa, K; Nishikawa, S; Shimoyama, M; Yakushijin, K; Yamamoto, K | 1 |
| Anastasiadou, E; Borrow, J; Dash, AB; Druker, B; Gilliland, DG; Housman, D; Kutok, JL; Li, S; Lindahl, K; Tomasson, MH; Van Etten, RA; Williams, IR | 1 |
70 review(s) available for imatinib mesylate and Disease Exacerbation
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Long-Term Care; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Long-term efficacy of imatinib for treatment of metastatic GIST.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Patient Compliance; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2013 |
The role of imatinib in the treatment of pulmonary hypertension.
Topics: Animals; Benzamides; Clinical Trials as Topic; Disease Progression; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2013 |
Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Benzamides; Bone Marrow; CD2 Antigens; Cladribine; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Mutation; Palliative Care; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Factors; Tryptases | 2013 |
[Case of primary retroperitoneal GIST (gastrointestinal stromal tumor) with rapid progression].
Topics: Antineoplastic Agents; Benzamides; Biopsy; Disease Progression; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Piperazines; Pyrimidines; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2013 |
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Topics: Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Management of advanced stage chronic myeloid leukemia].
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Progression; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2014 |
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; Disease Progression; Gabexate; Guanidines; Humans; Imatinib Mesylate; Immune System; Mast Cells; Neovascularization, Pathologic; NF-kappa B; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Stomach Neoplasms; Thiazoles; Tryptases | 2015 |
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Topics: Antineoplastic Agents; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Mutation; Odds Ratio; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Key messages from the BFR14 trial of the French Sarcoma Group.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sarcoma; Treatment Outcome | 2017 |
[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Survival Rate | 2008 |
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine | 2009 |
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Piperazines; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Response dynamics in chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome | 2009 |
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic | 2009 |
The impact of gene profiling in chronic myeloid leukaemia.
Topics: Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines | 2009 |
[Internal medical therapy of gastrointestinal stroma tumors].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Piperazines; Predictive Value of Tests; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Chronic myelogenous leukemia. Clinical practice guidelines in oncology.
Topics: Benzamides; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous | 2003 |
[Aspects of surgical treatment for gastro-intestinal stromal tumors].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnostic Imaging; Disease Progression; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Imatinib treatment for gastrointestinal stromal tumour (GIST).
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Why doesn't imatinib cure chronic myeloid leukemia?
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cytotoxins; Dermatofibrosarcoma; Disease Progression; Gastrointestinal Stromal Tumors; Hemangioendothelioma; Hemangiosarcoma; Humans; Imatinib Mesylate; Leiomyosarcoma; Liposarcoma, Myxoid; Piperazines; Pyrimidines; Research Design; Sarcoma; Sarcoma, Synovial; Skin Neoplasms | 2010 |
The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.
Topics: Apoptosis; Benzamides; Cell Differentiation; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species | 2007 |
Cytogenomics of cancers: from chromosome to sequence.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Chromosome Aberrations; Chromosomes; Cytogenetics; Disease Progression; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Gastrointestinal stromal tumors (GISTs): an updated experience.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnosis, Differential; Disease Progression; Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma; Cell Line; Disease Progression; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Melanoma; Piperazines; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Pyrimidines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Cells, Cultured; Up-Regulation | 2011 |
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Topics: Antineoplastic Agents; Benzamides; Cytogenetics; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Probability; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic eval
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Models, Economic; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome; Uncertainty; United States | 2011 |
High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2011 |
Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure.
Topics: Benzamides; Disease Progression; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2011 |
The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Autophagy; Benzamides; Blast Crisis; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Signal Transduction; src-Family Kinases | 2012 |
Chronic myelogenous leukemia for primary care physicians.
Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance; Drug Therapy, Combination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Thiazoles; Treatment Outcome; United Kingdom | 2012 |
[Translational research and diagnosis in GIST].
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Silencing; Germ-Line Mutation; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Mitotic Index; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Transcriptional Activation; Translational Research, Biomedical; Tumor Burden; Young Adult | 2012 |
Why imatinib remains an exception of cancer research.
Topics: Animals; Benzamides; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines | 2013 |
Resistance in the land of molecular cancer therapeutics.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2002 |
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Topics: Benzamides; Disease Progression; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2002 |
Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 2; Clinical Trials, Phase III as Topic; Clone Cells; Disease Progression; DNA-Binding Proteins; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Histone-Lysine N-Methyltransferase; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Philadelphia Chromosome; Piperazines; Proto-Oncogenes; Pyrimidines; Randomized Controlled Trials as Topic; Transcription Factors; Translocation, Genetic | 2003 |
Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Disease Progression; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-gamma; Interleukin-2; Life Tables; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.
Topics: Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oncogene Proteins v-abl; Piperazines; Pyrimidines | 2003 |
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Molecular Biology; Neoplasms; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2004 |
Current clinical management of gastrointestinal stromal tumors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Isoenzymes; Piperazines; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stromal Cells; Zinc Fingers | 2004 |
Natural history and staging of chronic myelogenous leukemia.
Topics: Benzamides; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2004 |
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.
Topics: Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Cohort Studies; Disease Progression; Hematopoiesis; Humans; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Myelodysplastic Syndromes; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2004 |
Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
Topics: Benzamides; Biomarkers, Tumor; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytoplasm; Disease Progression; Drug Design; Drug Industry; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2004 |
[Surgical management of GIST in the era of Gleevec].
Topics: Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Selection; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
[Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Topics: Antineoplastic Agents; Benzamides; Cancer Care Facilities; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Neoadjuvant Therapy; Patient Care Team; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
New developments in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Dimerization; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Piperazines; Prognosis; Pyrimidines | 2006 |
[Idiopathic interstitial pneumonia: treatment].
Topics: Acetylcysteine; Acute Disease; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Azathioprine; Benzamides; Bronchiolitis Obliterans; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colchicine; Cyclophosphamide; Diagnosis, Differential; Disease Progression; Female; Free Radical Scavengers; Humans; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sex Factors | 2006 |
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases | 2006 |
[Gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Advances in the treatment of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
The future is now for the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Piperazines; Pyrimidines | 2007 |
What's blasting off in CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Monitoring; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Pyrimidines; Risk Factors; Thiazoles | 2007 |
Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2008 |
Response evaluation of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Topics: Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines | 2007 |
85 trial(s) available for imatinib mesylate and Disease Exacerbation
| Article | Year |
|---|---|
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blast Crisis; Disease Progression; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2022 |
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Circulating Tumor DNA; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha | 2023 |
Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Phenotype; Philadelphia Chromosome; Protein Kinase Inhibitors; Quinolines; Time Factors; Treatment Outcome; Young Adult | 2018 |
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Topics: Adolescent; Antineoplastic Agents; Biomarkers; Bone Marrow; Child; Child, Preschool; Combined Modality Therapy; Disease Progression; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Treatment Failure; Treatment Outcome | 2018 |
Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chordoma; Disease Progression; Everolimus; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Sarcoma; Skull Base Neoplasms; Spinal Neoplasms; Survival Analysis | 2018 |
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2013 |
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Treatment Outcome; Withholding Treatment | 2013 |
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Benzimidazoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Sunitinib | 2013 |
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Republic of Korea; Sunitinib; Time Factors; Treatment Outcome | 2013 |
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antineoplastic Agents; Benzamides; Cytokines; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Kaposi; Time Factors; Treatment Outcome; United States | 2014 |
Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Patient Selection; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Time Factors; Treatment Outcome | 2014 |
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Disease Progression; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Imatinib Mesylate; Mutation; Prognosis; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate; Translational Research, Biomedical | 2016 |
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Longitudinal Studies; Middle Aged; Nitriles; Pyrimidines; Quinolines; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure | 2016 |
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Abdominal Neoplasms; Abdominal Wall; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Extremities; Female; Fibromatosis, Aggressive; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Multiple Primary; Positron-Emission Tomography; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Soft Tissue Neoplasms; Thoracic Neoplasms; Thoracic Wall; Treatment Outcome; Young Adult | 2017 |
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.
Topics: Abdominal Pain; Administration, Oral; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Survival Rate; Uveal Neoplasms | 2008 |
Phase II trial of imatinib mesylate in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Disease Progression; DNA Primers; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Skin Neoplasms; Treatment Outcome | 2008 |
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Statistics, Nonparametric; Treatment Outcome | 2008 |
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib | 2009 |
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Indoles; Markov Chains; Models, Econometric; Neoplasm Metastasis; Piperazines; Placebos; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Failure | 2008 |
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Topics: Benzamides; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2009 |
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2009 |
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Topics: Aged; Anemia; Benzamides; Disease Progression; Double-Blind Method; Dyspnea; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematoma, Subdural; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Leukopenia; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2010 |
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; src-Family Kinases; Thiazoles; Young Adult | 2010 |
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Disease Progression; Disease-Free Survival; Drug Therapy; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Outcome | 2009 |
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2010 |
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2010 |
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Fibroma; Follow-Up Studies; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Recurrence; Survival Analysis | 2011 |
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2010 |
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Adenoid Cystic; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography, Thoracic; Radiopharmaceuticals; Remission Induction; Salivary Gland Neoplasms; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2011 |
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Piperazines; Pyrimidines | 2011 |
Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Cells; Bone Marrow Cells; Disease Progression; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Peptide Fragments; Piperazines; Protein Isoforms; Pyrimidines; Survivin; T-Lymphocytes, Cytotoxic; Treatment Outcome; Young Adult | 2011 |
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Child; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Topics: Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2012 |
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2012 |
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Young Adult | 2012 |
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2012 |
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome | 2012 |
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.
Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Sarcoma; Treatment Outcome | 2013 |
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Count; Cytogenetic Analysis; Disease Progression; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Megakaryocytes; Piperazines; Pyrimidines; Thrombocytopenia; Time Factors | 2002 |
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Survival Rate | 2003 |
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Topics: Adolescent; Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Cytogenetic Analysis; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines | 2003 |
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Imatinib in small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2003 |
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Pyrimidines; Survival Analysis; Treatment Failure; Treatment Outcome | 2003 |
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of imatinib in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2003 |
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Topics: Acute Disease; Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Transplantation, Homologous | 2004 |
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2004 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Edema; Fatigue; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Failure | 2005 |
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Chi-Square Distribution; Chromatography, High Pressure Liquid; Cytogenetic Analysis; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Point Mutation; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Statistics, Nonparametric; Survival Analysis | 2005 |
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzamides; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quality of Life; Receptors, Platelet-Derived Growth Factor; Surveys and Questionnaires; Survival Rate | 2006 |
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Mesothelioma; Middle Aged; Piperazines; Pleural Neoplasms; Pyrimidines; Survival Analysis; Treatment Outcome | 2005 |
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Salvage Therapy; Survival Rate | 2005 |
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Over Studies; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Grou
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrimidines; Treatment Outcome | 2005 |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Carcinoma, Adenoid Cystic; Disease Progression; DNA Mutational Analysis; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Piperazines; Pleural Effusion, Malignant; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
A phase II trial of imatinib in patients with refractory/relapsed myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Male; Middle Aged; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Treatment Failure | 2006 |
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis | 2005 |
Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Salvage Therapy; Testicular Neoplasms; Treatment Outcome | 2006 |
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Mesothelioma; Middle Aged; Pilot Projects; Piperazines; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stem Cell Factor; Treatment Failure | 2007 |
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Phthalazines; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy | 2008 |
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Virginia | 2007 |
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy | 2007 |
[Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Female; Follow-Up Studies; Hematopoiesis; Humans; Imatinib Mesylate; Incidence; Leukemia, Myeloid, Chronic-Phase; Leukocyte Count; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Russia; Survival Rate; Time Factors | 2007 |
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2008 |
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Topics: Aged; Albumins; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukocyte Count; Male; Multivariate Analysis; Mutation; Neutrophils; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Survival Rate | 2008 |
A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Piperazines; Pyrimidines; Time Factors | 2008 |
249 other study(ies) available for imatinib mesylate and Disease Exacerbation
| Article | Year |
|---|---|
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Disease Models, Animal; Disease Progression; DNA Breaks, Double-Stranded; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Ontology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Mice, Inbred C57BL; MicroRNAs; RNA, Messenger; Up-Regulation | 2021 |
Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Topics: Apoptosis; Cell Cycle; Chronic Disease; Cytokines; Disease Progression; DNA; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Surveys and Questionnaires; Tumor Suppressor Protein p14ARF | 2022 |
Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
Topics: Antineoplastic Agents; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
From Morphea to Dermatofibrosarcoma Protuberans.
Topics: Adult; Cicatrix; Dermatofibrosarcoma; Disease Progression; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Scleroderma, Localized; Skin Neoplasms; Young Adult | 2022 |
[Gastrointestinal stromal tumors: a retrospective study].
Topics: Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Retrospective Studies | 2023 |
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.
Topics: Adult; Antineoplastic Agents; Australia; Disease Progression; Disease-Free Survival; Europe; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Receptors, Colony-Stimulating Factor; Retrospective Studies; Treatment Outcome; United States | 2019 |
Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Membrane; Disease Models, Animal; Disease Progression; Female; Imatinib Mesylate; Inflammation; Lung Neoplasms; Membrane Potentials; Mitochondria; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Signal Transduction; Tumor Microenvironment | 2020 |
Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells.
Topics: Aldehyde Dehydrogenase 1 Family; Apoptosis; Carcinogenesis; Cell Lineage; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Protein Kinase Inhibitors; Telomerase | 2020 |
Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?
Topics: Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Sunitinib | 2020 |
COVID-19 in persons with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Betacoronavirus; Child; China; Coronavirus Infections; COVID-19; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prevalence; Protein Kinase Inhibitors; Risk Factors; SARS-CoV-2; Surveys and Questionnaires | 2020 |
[Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Patient Care Team; Sunitinib; Treatment Outcome; Tumor Burden | 2020 |
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Decision Support Techniques; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Progression-Free Survival; Protein Kinase Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2020 |
Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
Topics: Adult; Aged; Decision Making; Digestive System Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Registries; Retrospective Studies; Time Factors | 2021 |
Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.
Topics: Animals; Biomarkers; Discoidin Domain Receptor 1; Discoidin Domain Receptor 2; Discoidin Domain Receptors; Disease Models, Animal; Disease Outbreaks; Disease Progression; Fibrosis; Gene Expression Regulation; Humans; Imatinib Mesylate; Immunohistochemistry; Mice; Pancreatitis, Chronic; Protein Kinase Inhibitors; Signal Transduction | 2021 |
A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis.
Topics: Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Skin | 2017 |
An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
Topics: Antineoplastic Agents; China; Chronic Disease; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Treatment Outcome | 2017 |
Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
Topics: Antineoplastic Agents; China; Cost-Benefit Analysis; Dasatinib; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Substitution; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2018 |
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Association Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Retrospective Studies; Risk Factors; Solute Carrier Organic Anion Transporter Family Member 1B3; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Cohort Studies; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Random Allocation; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Transcriptome | 2018 |
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Progression-Free Survival; Sarcoma; Time Factors | 2019 |
Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia.
Topics: Antineoplastic Agents; Biopsy; Disease Progression; Endocardium; Endomyocardial Fibrosis; Heart Failure; Heart Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Myocardium; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Germ Cells; Humans; Imatinib Mesylate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Mutation; Polymorphism, Single Nucleotide | 2019 |
Topics: Blast Crisis; Cell Differentiation; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Sequence Analysis, DNA; Ubiquitin-Conjugating Enzymes | 2019 |
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Topics: Adult; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Safety-Based Drug Withdrawals; Treatment Outcome | 2019 |
Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Prognosis; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2019 |
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Topics: Adult; Aged; Antineoplastic Agents; Cardiovascular Diseases; Disease Progression; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferons; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
[Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia, in Abidjan, Ivory Coast].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Chromosome Aberrations; Cote d'Ivoire; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Cells, Circulating; Philadelphia Chromosome; Prognosis; Remission Induction; Retrospective Studies; Socioeconomic Factors; Young Adult | 2019 |
Prognosis assessment in metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors based on CT-texture analysis.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
MicroRNA signature refine response prediction in CML.
Topics: Adult; Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tumor Cells, Cultured | 2019 |
PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib.
Topics: Adult; Disease Progression; Genetic Predisposition to Disease; Heterozygote; Humans; Imatinib Mesylate; Male; Mutation; Myofibromatosis; Receptor, Platelet-Derived Growth Factor beta | 2019 |
Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.
Topics: Adult; Aged; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Propensity Score; Treatment Outcome | 2019 |
Imatinib prevents elastase-induced abdominal aortic aneurysm progression by regulating macrophage-derived MMP9.
Topics: Animals; Aortic Aneurysm, Abdominal; Disease Progression; Gene Expression Regulation, Enzymologic; Imatinib Mesylate; Macrophages; Male; Matrix Metalloproteinase 9; Pancreatic Elastase; Phosphorylation; Rats; Rats, Sprague-Dawley; STAT3 Transcription Factor | 2019 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers; Child; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation Rate; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2013 |
Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Liver Neoplasms; Middle Aged; Osteonecrosis; Pain; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Tibia | 2013 |
NCCN Task Force report: gastrointestinal stromal tumor (GIST).
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2004 |
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Databases, Factual; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2013 |
Spontaneous hemoperitoneum in recurrent jejunal gastrointestinal stromal tumor after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Jejunum; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2013 |
Rapid left ventricular thickening and thrombus caused by FIP1L1/PDGFRA-negative hypereosinophilic syndrome.
Topics: Benzamides; Biopsy; Cerebral Infarction; Disease Progression; Echocardiography; Fibrosis; Genetic Predisposition to Disease; Hemodynamics; Humans; Hypereosinophilic Syndrome; Hypertrophy, Left Ventricular; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Phenotype; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Thrombosis; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2013 |
Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Drug Utilization Review; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; United States; Veterans | 2013 |
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.
Topics: Animals; Benzamides; Blast Crisis; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunophenotyping; Interferon Regulatory Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cells; Neoplastic Stem Cells; Piperazines; Pyrimidines; Side-Population Cells; Wnt Signaling Pathway | 2013 |
Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat.
Topics: Animals; Benzamides; Chronic Disease; Disease Progression; Glomerulonephritis, Membranoproliferative; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Thy-1 Antigens; Treatment Outcome | 2013 |
[Particular evolution of complex cytogenetic variants of chronic myeloid leukemia treated with imatinib].
Topics: Adult; Benzamides; Cytogenetic Analysis; Disease Progression; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Translocation, Genetic; Young Adult | 2013 |
Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
Topics: Animals; Antineoplastic Agents; Benzamides; Caspases; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Humans; Imatinib Mesylate; Immunocompetence; Male; Mice; Mice, Inbred C57BL; Mitosis; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Substitution; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Child; Disease Progression; DNA Methylation; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrimidines; RNA, Messenger; STAT5 Transcription Factor; Young Adult | 2014 |
[A case report of two-term surgery for focal progression of a huge liver metastasis and peritoneal dissemination from gastrointestinal stromal tumor during imatinib mesylate treatment].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Stomach Neoplasms | 2014 |
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Therapy: This time it's personal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Evolution; Biopsy; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Delivery Systems; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Genetics, Medical; Genomics; Humans; Imatinib Mesylate; Immunotherapy; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nanoparticles; Neoplasms; Pharmacogenetics; Piperazines; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyrimidines; RNA Interference; RNA, Small Interfering; Sulfonamides; Time Factors; Transcriptome; Vemurafenib | 2014 |
The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Propensity Score; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2014 |
A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum.
Topics: Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease Progression; Dissection; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Postoperative Complications; Pyrimidines; Risk Assessment; Rupture, Spontaneous | 2015 |
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Genes, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; RNA, Small Interfering; Survival Analysis; Up-Regulation | 2014 |
The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sex Factors | 2014 |
Clinicopathologic analysis of gastrointestinal stromal tumors in duodenum and small intestine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Duodenal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Mitotic Index; Neoplasm Staging; Piperazines; Pyrimidines; Retrospective Studies; Rupture, Spontaneous; Survival Analysis; Survival Rate; Young Adult | 2015 |
[Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Failure; Young Adult | 2014 |
Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor.
Topics: Abdominal Wall; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Mutation; Paraganglioma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Rectal Neoplasms; Succinate Dehydrogenase; Treatment Outcome | 2016 |
[The importance of mutational status in prognosis and therapy of GIST].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib | 2015 |
Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
Topics: Antineoplastic Agents; Blast Crisis; Child; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Deletion; Genetic Variation; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
gDNA Q-PCR for clinical monitoring of CML.
Topics: Disease Progression; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymerase Chain Reaction; Protein Kinase Inhibitors; Recurrence; Remission Induction; RNA, Messenger; Treatment Outcome | 2015 |
[A case of recurrent gastrointestinal stromal tumor progressing after interruption of long-term imatinib therapy].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors | 2014 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
[Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2015 |
The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia; Biomarkers, Tumor; Canada; Digestive System Surgical Procedures; Disease Progression; DNA Mutational Analysis; Europe; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Registries; Risk Factors; South America; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2015 |
Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate | 2016 |
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Time Factors | 2016 |
Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
Topics: Adult; Aged; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Treatment Outcome; WT1 Proteins | 2015 |
Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Health Services; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Middle Aged; Models, Econometric; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Monitoring; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Stomach; Treatment Outcome | 2016 |
Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Fear; Germany; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Outpatients; Prospective Studies; Protein-Tyrosine Kinases; Surveys and Questionnaires | 2016 |
The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Mutation; Pyrimidines; Retrospective Studies; RNA-Binding Proteins; RNA, Messenger; Survival Analysis | 2016 |
High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
Topics: Apoptosis; Blast Crisis; Bone Marrow; Cells, Cultured; Coculture Techniques; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Signal Transduction | 2016 |
MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression.
Topics: CCAAT-Enhancer-Binding Proteins; Disease Progression; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MEF2 Transcription Factors; Neoplasm Staging; Up-Regulation | 2016 |
Molecular Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib - Single Centre Experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Remission Induction; Republic of North Macedonia; Time Factors; Treatment Outcome; Young Adult | 2015 |
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult | 2017 |
A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.
Topics: Adult; Aged; Alleles; Case-Control Studies; Disease Progression; DNA-Binding Proteins; Female; Fusion Proteins, bcr-abl; Genotype; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; INDEL Mutation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Polymorphism, Genetic; Sequence Deletion; Transcription Factors; Translocation, Genetic; Treatment Outcome | 2017 |
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
[Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Pyrimidines | 2016 |
[Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia.
Topics: Aged; Cytidine Deaminase; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Microfilament Proteins; Oncogene Proteins; Protein Kinase Inhibitors | 2017 |
Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Pioglitazone with imatinib in CML may reduce residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Pioglitazone; Protein Kinase Inhibitors; Thiazolidinediones; Treatment Outcome | 2017 |
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Giant gastric gastrointestinal stromal tumor with severe peritoneal dissemination controlled by imatinib therapy following debulking surgery: a case report.
Topics: Abdominal Pain; Anorexia; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparotomy; Middle Aged; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Myeloid Sarcoma as the First Sign of Progression of Chronic Myeloid Leukemia in Medullary Chronic Phase: Experience from a Tertiary Cancer Centre in Southern India.
Topics: Adult; Disease Progression; Female; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Sarcoma, Myeloid | 2017 |
Disease progression in some cancers may be due to low blood levels of targeted therapies.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines | 2008 |
Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Middle Aged; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrimidines; Treatment Outcome | 2008 |
Is imatinib mesylate a promising drug in systemic sclerosis?
Topics: Aged; Benzamides; Collagen; Disease Progression; Female; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Scleroderma, Systemic; Treatment Outcome | 2008 |
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Biomarkers, Tumor; Biopsy; Cetuximab; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Lymph Nodes; Male; Neoplasms, Hormone-Dependent; Piperazines; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Taxoids; Trastuzumab | 2008 |
FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Female; fms-Like Tyrosine Kinase 3; Genotype; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Disease Progression; HSP70 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Prognosis; Pyrimidines; Young Adult | 2009 |
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Topics: Adult; Aged; Benzamides; Cell Differentiation; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Factor | 2009 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling | 2008 |
[Tolerability of imatinib for patients with chronic myelogeneous leukemia (CML)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Survival Rate; Young Adult | 2008 |
Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Korea; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Rate; Treatment Failure | 2009 |
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Neoplasm Staging; Piperazines; Pyrimidines; Survival Rate; Time Factors; Trisomy | 2009 |
Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Korea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; China; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome | 2009 |
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Cells; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; RNA, Messenger; RNA, Neoplasm; Young Adult | 2009 |
Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Amino Acid; Receptors, Platelet-Derived Growth Factor; Survival Analysis; Treatment Outcome | 2009 |
Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Risk Factors; Time Factors; Translocation, Genetic; Treatment Outcome | 2009 |
Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Risk Factors; Translocation, Genetic; Treatment Outcome | 2009 |
A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chimera; Chromosomes, Human, Pair 9; Chromosomes, Human, X; Chromosomes, Human, Y; Disease Progression; Fertility; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidental Findings; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Piperazines; Polycythemia Vera; Pyrimidines; Sex Chromosome Aberrations; Trisomy | 2009 |
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Futility; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2010 |
In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cecal Neoplasms; Cell Proliferation; Disease Progression; Exons; Female; Gastrointestinal Stromal Tumors; Gene Knock-In Techniques; Heterozygote; Imatinib Mesylate; Ki-67 Antigen; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Phosphorylation; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Signal Transduction | 2009 |
The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Fusion Proteins, bcr-abl; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Ribonucleoproteins; Signal Transduction; Young Adult | 2010 |
Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Cytidine Deaminase; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Mutation; Piperazines; Pyrimidines | 2009 |
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cohort Studies; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2010 |
A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Molecular characterization and prognostic significance of FLT3 in CML progression.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Disease Progression; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Piperazines; Prognosis; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2010 |
Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2010 |
A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polycythemia Vera; Pyrimidines | 2010 |
Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2010 |
Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era.
Topics: Adolescent; Adult; Age Factors; Aged; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pakistan; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2009 |
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic | 2010 |
Studies on lipid peroxidation and non-enzymatic antioxidant status as indices of oxidative stress in patients with chronic myeloid leukaemia.
Topics: Adult; Antioxidants; Benzamides; Biomarkers; Case-Control Studies; Disease Progression; Female; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfhydryl Compounds | 2010 |
Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression.
Topics: Administration, Oral; Animals; Benzamides; Disease Models, Animal; Disease Progression; Imatinib Mesylate; Liver Cirrhosis; Liver Function Tests; Male; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar; Silymarin; Thioacetamide | 2011 |
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2010 |
Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sequence Deletion; Sunitinib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Case-Control Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leiomyoma; Male; Middle Aged; Midkine; Neoplasm Recurrence, Local; Neoplasm Staging; Nerve Growth Factors; Piperazines; Prognosis; Pyrimidines; Survival Rate; Tissue Array Analysis | 2011 |
Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger; Thiazoles | 2010 |
Nonadherence to imatinib during an economic downturn.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Economic Recession; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Compliance; Piperazines; Pyrimidines | 2010 |
Imatinib treatment of metastatic GIST: don't stop (believing).
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement.
Topics: Benzamides; Brain Neoplasms; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2011 |
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Molecular Sequence Data; Peritoneal Neoplasms; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2011 |
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Topics: Animals; Benzamides; Binding Sites; Biomarkers, Tumor; Cell Line, Tumor; Cell Lineage; Cell Survival; Cell Transformation, Neoplastic; Disease Progression; DNA-Binding Proteins; Enhancer Elements, Genetic; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mutant Proteins; Mutation; NIH 3T3 Cells; Oncogenes; Piperazines; Protein Stability; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Transcription Factors | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intention to Treat Analysis; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2010 |
Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2010 |
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Failure | 2012 |
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mitosis; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Tumor Burden | 2010 |
Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Salvage Therapy; Treatment Outcome | 2011 |
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cells, Cultured; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Piperazines; Prognosis; Pyrimidines; STAT5 Transcription Factor; Treatment Failure; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Topics: Benzamides; Disease Progression; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Telomerase; WT1 Proteins | 2011 |
Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Disease Progression; DNA Mutational Analysis; DNA Primers; Exons; Female; Gastrointestinal Stromal Tumors; Genetics, Population; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Switzerland | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis.
Topics: Animals; Benzamides; Biopsy; Cell Line, Tumor; Disease Progression; Epigenesis, Genetic; Female; Gene Silencing; Helicobacter pylori; Humans; Imatinib Mesylate; Lymphoma, B-Cell, Marginal Zone; Mice; Mice, Inbred BALB C; MicroRNAs; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-abl; Piperazines; Pyrimidines; Stomach Neoplasms | 2011 |
MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Progression; DNA Replication; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myc; Pyrimidines | 2011 |
Stochastic dynamics of leukemic cells under an intermittent targeted therapy.
Topics: Benzamides; Computer Simulation; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stochastic Processes | 2011 |
Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2011 |
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Basophils; Benzamides; Disease Progression; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Statistical; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Registries; Risk Assessment; Risk Factors; Spleen; Young Adult | 2011 |
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2011 |
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Argentina; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2011 |
Fibrosis, regeneration, and aging: playing chess with evolution.
Topics: Aging; Animals; Antineoplastic Agents; Benzamides; Biological Evolution; Cytokines; Disease Progression; Fibrosis; Humans; Imatinib Mesylate; Immune System; Inflammation; Kidney Failure, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Regeneration | 2011 |
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Benzamides; Cell Line, Tumor; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Genes, Neoplasm; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Line, Tumor; Cyclohexanones; Disease Progression; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Luminescent Measurements; Mice; Neoplasm Proteins; NF-kappa B; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Fusion Proteins; Spleen; Stromal Cells; Transgenes; Transplantation, Heterologous; Tumor Burden; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2011 |
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
Topics: Animals; Anisoles; Astrocytes; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Proliferation; Cells, Cultured; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Imatinib Mesylate; Macrophages; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Sorafenib; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2011 |
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Child; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Nomograms; Piperazines; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Tumor Burden; Young Adult | 2011 |
HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers.
Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Coculture Techniques; Culture Media, Conditioned; Disease Progression; Female; Fibroblasts; HeLa Cells; Heparin-binding EGF-like Growth Factor; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Mice, Nude; Neoplasm Proteins; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Stromal Cells; Tumor Cells, Cultured; Tyrphostins; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome | 2011 |
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.
Topics: Adult; Aged; Benzamides; Blast Crisis; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
First-line treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia: experience of a public hospital in a developing country of South America.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Brazil; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hospitals, Public; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transcription, Genetic; Treatment Outcome; Young Adult | 2012 |
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Disease Management; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Time Factors | 2012 |
Gastrointestinal stromal tumors (GIST): a single center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Length of Stay; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2012 |
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Disease Progression; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Home Care Services; Humans; Imatinib Mesylate; Medication Adherence; Monitoring, Physiologic; Piperazines; Practice Guidelines as Topic; Precision Medicine; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2012 |
Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Benzamides; Collagen Type I; Creatinine; Disease Progression; Female; Fluorescent Antibody Technique; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proteinuria; Pyrimidines; Rats; Rats, Inbred WKY; Real-Time Polymerase Chain Reaction; Renal Insufficiency, Chronic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transforming Growth Factor beta | 2013 |
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Organic Cation Transport Proteins; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrimidines; Solute Carrier Family 22 Member 5; Symporters; Young Adult | 2013 |
Tumor volume as an alternative response measurement for imatinib treated GIST patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Automation; Benzamides; Cohort Studies; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imaging, Three-Dimensional; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Piperazines; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle Proteins; Computer Systems; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Disease Progression; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vorinostat | 2003 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
Topics: Benzamides; Clone Cells; Disease Progression; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2002 |
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA, Complementary; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA; Treatment Outcome | 2003 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Topics: Adenosine Triphosphate; Adult; Aged; Benzamides; Binding Sites; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Prognosis; Protein Structure, Tertiary; Pyrimidines; Survival Analysis | 2003 |
Cytogenetic and molecular mechanisms of resistance to imatinib.
Topics: Benzamides; Chromosome Aberrations; Clone Cells; Cytogenetic Analysis; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Pyrimidines; RNA, Neoplasm; Treatment Outcome | 2003 |
Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Risk; RNA; RNA, Messenger; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2003 |
Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Monocytic, Acute; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Disease Progression; Genotype; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Models, Genetic; Multivariate Analysis; Phenotype; Piperazines; Polymorphism, Genetic; Pyrimidines; Time Factors; Treatment Outcome | 2004 |
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Proportional Hazards Models; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2004 |
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Sequence Deletion; Thymoma; Thymus Neoplasms | 2004 |
Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cells, Cultured; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; T-Lymphocytes; Telomere; Time Factors | 2004 |
Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Cytogenetic Analysis; Disease Progression; Fibrosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2004 |
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Topics: Alleles; Antineoplastic Agents; Base Sequence; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation, Missense; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Stromal Cells | 2004 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance; Enzyme Inhibitors; Gene Rearrangement; Humans; Hydroxyurea; Imatinib Mesylate; Leukocytosis; Male; Middle Aged; Mutant Proteins; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Splenectomy; Splenomegaly; Thrombocytopenia; Translocation, Genetic; Treatment Failure | 2004 |
Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Piperazines; Prednisolone; Pyrimidines; Recurrence; Rituximab; Vincristine | 2004 |
Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Bone Marrow Transplantation; Community Networks; Cross-Sectional Studies; Databases, Factual; Disease Progression; Female; France; Health Services Accessibility; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins | 2005 |
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Treatment Outcome | 2004 |
Accessing key steps of human tumor progression in vivo by using an avian embryo model.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Chick Embryo; Disease Models, Animal; Disease Progression; DNA Primers; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Imatinib Mesylate; In Situ Hybridization; Oligonucleotide Array Sequence Analysis; Piperazines; Polymerase Chain Reaction; Pyrimidines; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult | 2005 |
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow Transplantation; Disease Progression; Europe; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Factors; Societies, Scientific; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2005 |
[FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; DNA, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotyping; Male; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.
Topics: Administration, Oral; Animals; Benzamides; Biomarkers; Collagen Type I; Disease Progression; Follow-Up Studies; Imatinib Mesylate; Liver Cirrhosis, Experimental; Male; Mass Spectrometry; Matrix Metalloproteinase 2; Piperazines; Procollagen; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2006 |
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Inhibitory Concentration 50; Macrophage Colony-Stimulating Factor; Mice; Mutation; Neoplasms; Oncogene Protein v-cbl; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Time Factors; Valine | 2006 |
Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; CpG Islands; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Long Interspersed Nucleotide Elements; Male; Middle Aged; Multivariate Analysis; Open Reading Frames; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrimidines; Regression Analysis; Retroelements; Transcription, Genetic; Treatment Outcome | 2005 |
Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Chronic myelogenous leukemia.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous | 2005 |
Thymic carcinoma in a child with HIV infection.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Disease Progression; Follow-Up Studies; HIV Infections; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Mediastinal Cyst; Piperazines; Pyrimidines; Remission Induction; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.
Topics: Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Mice; Mice, Transgenic; Mutation; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidines; Time Factors; Trans-Activators | 2005 |
[Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2005 |
Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Decision Making; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Remission Induction; Stomach Neoplasms; Survival Analysis; Tomography, Spiral Computed | 2006 |
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Topics: Abortion, Spontaneous; Adult; Antineoplastic Agents; Benzamides; Congenital Abnormalities; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Records; Metaphase; Philadelphia Chromosome; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Retrospective Studies; Teratogens | 2006 |
Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leydig Cell Tumor; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Testicular Neoplasms; Treatment Failure | 2006 |
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA-Binding Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Imatinib Mesylate; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peptide Elongation Factor 1; Piperazines; Pyrimidines; Recurrence; Transcription Factors | 2006 |
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow; Chromosome Aberrations; Cloning, Molecular; Cytogenetic Analysis; Disease Progression; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines; Reproducibility of Results; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Treatment Outcome | 2006 |
Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis.
Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines | 2006 |
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines; Remission Induction | 2006 |
hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzamides; Carrier Proteins; Cell Cycle Proteins; Disease Progression; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA-Binding Proteins; Sensitivity and Specificity; Tankyrases; Telomerase; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Transcription, Genetic; Tumor Suppressor Proteins | 2006 |
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Retrospective Studies | 2006 |
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Tumor Cells, Cultured | 2006 |
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Topics: Animals; Benzamides; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Knockout; Mutation; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Rate; Tumor Suppressor Protein p53 | 2006 |
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Kinase inhibitors in chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles | 2006 |
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Centrosome; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Piperazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases.
Topics: Aged; Antineoplastic Agents; Benzamides; Cysts; Diagnostic Errors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2006 |
Antivascular therapy of cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor | 2006 |
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Basophilic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Demography; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2006 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chordoma; Disease Progression; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sensitivity and Specificity | 2007 |
Chronic myeloid leukemia blast crisis arises from progenitors.
Topics: Benzamides; Blast Crisis; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Immunological; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2007 |
Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytogenetic Analysis; Disease Progression; Fatal Outcome; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Recurrence; Treatment Failure | 2007 |
Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy.
Topics: Benzamides; Biopsy; Bone Marrow; Disease Progression; Follow-Up Studies; Glomerular Basement Membrane; Glomerulonephritis, Membranoproliferative; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesangial Cells; Microscopy, Electron; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Effective neoadjuvant therapy prior to metastasectomy: a new paradigm.
Topics: Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Protocols; Databases, Factual; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Pyrimidines; Registries; Transplantation, Homologous; United States | 2007 |
Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
We should desist using RECIST, at least in GIST.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2007 |
Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 7; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Disease Progression; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells | 2008 |
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
Topics: Benzamides; Blood Cell Count; Blood Platelets; Cell Line; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Small Interfering; Transcription, Genetic; Transfection | 2007 |
Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Topics: Antineoplastic Agents; Benzamides; Cytogenetics; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Treatment Outcome | 2006 |
A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytogenetic Analysis; Disease Progression; Exons; Female; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Time Factors; Translocation, Genetic; Treatment Outcome | 2007 |
Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.
Topics: Adult; Aneugens; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monosomy; Piperazines; Pyrimidines; Translocation, Genetic | 2007 |
New strategies for treating GIST when imatinib fails.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sarcoma; Tomography, X-Ray Computed; Treatment Failure | 2007 |
Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL.
Topics: Animals; Antineoplastic Agents; Benzamides; Burkitt Lymphoma; Disease Progression; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice; Models, Biological; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2007 |
Progressive thoughts about progressive disease.
Topics: Antineoplastic Agents; Benzamides; Clone Cells; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines | 2007 |
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Imatinib Mesylate; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Program Development; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Time Factors | 2008 |
Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Telomerase | 2008 |
Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Deletion; Genes, abl; Genes, p53; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2008 |
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Bone Marrow Transplantation; Cell Division; Cloning, Molecular; Disease Models, Animal; Disease Progression; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Proteins; Mice; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Piperazines; Proviruses; Pyrimidines; Tumor Cells, Cultured | 2002 |